Literature DB >> 101223

Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol.

G Jackson, J D Harry, C Robinson, D Kitson, D E Jewitt.   

Abstract

Fourteen patients with angina pectoris completed a double blind trial of atenolol 25 mg, 50 mg, and 100 mg twice daily and propranolol 80 mg thrice daily. In comparison with placebo, all active treatments significantly reduced anginal attacks, consumption of glyceryl trinitrate, resting and exercise heart rate, resting and exercise systolic blood pressure, and significantly prolonged exercise time. There was no significant difference between the effects of propranolol and atenolol. Nine patients completed a further trial comparing atenolol given once or twice daily. Both regimens were effective and there was no significant difference between the reductions in anginal attacks, glyceryl trinitrate consumption, systolic blood pressure, or heart rate. Twenty-four-hour ambulatory electrocardiograms showed that atenolol consistently reduced heart rate throughout the 24-hour period whether given once or twice daily. Atenolol is a potent antianginal agent which, in most patients, is likely to be effective once daily.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101223      PMCID: PMC483523          DOI: 10.1136/hrt.40.9.998

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  10 in total

1.  Medical ethics.

Authors:  R Ormrod
Journal:  Br Med J       Date:  1968-04-06

2.  Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Med J       Date:  1975-09-13

3.  The demonstration of atenolol as a beta-adrenoceptor blocking drug in man.

Authors:  J D Harry
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Unwanted effects of propranolol.

Authors:  S A Stephen
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

5.  Withdrawal of propranolol and myocardial infarction.

Authors:  R G Diaz; J C Somberg; E Freeman; B Levitt
Journal:  Lancet       Date:  1973-05-12       Impact factor: 79.321

6.  Withdrawal of propranolol and myocardial infarction.

Authors:  R Slome
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

7.  Withdrawal of propranolol and myocardial infarction.

Authors:  M Nellen
Journal:  Lancet       Date:  1973-03-10       Impact factor: 79.321

8.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

9.  Coronary artery syndromes after sudden propranolol withdrawal.

Authors:  E L Alderman; D J Coltart; G E Wettach; D C Harrison
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

10.  Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Med J       Date:  1975-03-29
  10 in total
  10 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 2.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

3.  Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial.

Authors:  T Baba; S Murabayashi; K Takebe
Journal:  Diabetologia       Date:  1989-01       Impact factor: 10.122

4.  Medical treatment of patients with severe exertional and rest angina: double blind comparison of beta blocker, calcium antagonist, and nitrate.

Authors:  A A Quyyumi; T Crake; C M Wright; L J Mockus; K M Fox
Journal:  Br Heart J       Date:  1987-06

5.  Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol.

Authors:  A A Quyyumi; C Wright; L Mockus; K M Fox
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-13

6.  Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease.

Authors:  M Condorelli; G Brevetti; M Chiariello; D Miceli; G Lavecchia; G Paudice; S Verrienti
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of atenolol--a review.

Authors:  W Kirch; K G Görg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

8.  Haemodynamic and metabolic effects of atenolol in patients with angina pectoris.

Authors:  D S Thompson; N Naqvi; S M Juul; D J Coltart; B S Jenkins; M M Webb-Peploe
Journal:  Br Heart J       Date:  1980-06

9.  Comparison of once and twice daily sotalol in exercise-induced angina pectoris.

Authors:  C Wilhelmsson; A Vedin; G Ulvenstam; A Aberg; R Descamps; J A Thomis
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Oral labetalol in the management of stable angina pectoris in normotensive patients.

Authors:  J W Upward; F Akhras; G Jackson
Journal:  Br Heart J       Date:  1985-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.